MK-677 (ibutamoren)
Not a peptide — oral growth-hormone release-nudge (secretagogue) -R medicines that activate their target pathway; not FDA-approved.
What it's for
Not a peptide — oral growth-hormone release-nudge (secretagogue) -R medicines that activate their target pathway; not FDA-approved.
What it's for
Ibutamoren (MK-677) is an orally active ghrelin medicine that turns a receptor signal on small molecule often listed beside peptides in consumer libraries.
What it does for the body
Raises growth hormone and IGF-1 in studies; investigated for frailty, growth hormone deficiency, and Alzheimer’s. Not FDA-approved. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
growth-hormone release-nudge (secretagogue) -R1a activating its target pathway increases growth hormone pulsatility similarly to ghrelin, with appetite and glucose-effect caveats. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: MK-677 (ibutamoren) is best treated as a research-interest topic. Early papers can be fascinating; they are not a green light for self-experimentation.
Studied for (literature interest)
- Bones research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: MK-677 (ibutamoren) — FDA.gov search
- ClinicalTrials.gov search: MK-677 (ibutamoren) — U.S. clinical trials registry
- Drugs@FDA search: MK-677 (ibutamoren) — FDA drug database (if approved)
- PubMed search: MK-677 (ibutamoren) — NCBI PubMed
- PubMed Central search: MK-677 (ibutamoren) — NCBI PMC